 |
|
|
|
 |
|
|
| Article 1 to 10 out of 16 concerning Cenix BioScience GmbH
|
-
Cenix BioScience expands relationship with AstraZeneca, signing multi-project research agreement
(17 Jun 2009)
Cenix BioScience GmbH announced that they have signed a new multi-project research agreement with AstraZeneca, thereby expanding their relationship beyond its initial oncology focus, to now include respiratory and inflammation-related indications. ...
-
Cenix BioScience Signs Research Agreement with Boehringer Ingelheim for RNAi-Based Target Discovery
(04 Feb 2009)
Cenix BioScience GmbH announced that it has signed a research agreement to support Boehringer Ingelheim in its ongoing efforts to discover novel therapeutic drug targets.Cenix will apply its expertise in combining high throughput (HT) applications ...
-
IMM, Cenix and Alnylam Discover New Targets in Malaria Infection with RNAi Technology
(13 Nov 2008)
In Vitro and In Vivo Findings Published in the Journal PLoS Pathogens Identify Novel Host Targets Involved in Malaria Infection
Alnylam Pharmaceuticals, Inc. and Cenix BioScience GmbH announced the publication of a new study in the journal PLoS Pathogens demonstrating in vitro and in vivo RNAi-mediated silencing of novel host factors involved in malaria infection. The work ...
-
Instituto de Medicina Molecular, Cenix BioScience, and Alnylam Pharmaceuticals discover new pathway for malaria infection
(15 Sep 2008)
New research using RNAi technologies published on the first molecular link between malaria and the host cholesterol uptake pathway
Cenix BioScience GmbH, Alnylam Pharmaceuticals, Inc. and the Lisbon-based biomedical research centre Instituto de Medicina Molecular (IMM) announced the publication of their collaborative study in Cell Host & Microbe, describing the discovery and in ...
-
Cenix BioScience Signs Research Agreement with Regulus Therapeutics for miRNA-Targeted Drug Discovery
(23 Jul 2008)
Cenix BioScience GmbH announced that they have signed a research agreement with Regulus Therapeutics LLC to advance the latter's efforts in the discovery of novel therapeutic miRNA modulators.Cenix will apply its expertise in combining high ...
-
Cenix BioScience and CellCentric Sign Framework Research Agreement for RNAi-Based Target Validation.
(26 Mar 2008)
Cenix BioScience GmbH announced that it has signed a framework research agreement to support CellCentric Ltd through cell-based validation of novel therapeutic drug targets for oncology.Cenix will apply its expertise in combining high throughput ...
-
Cenix BioScience Signs Framework Research Agreement with AstraZeneca for RNAi-Based Drug Discovery.
(25 Mar 2008)
Cenix BioScience GmbH (Dresden) announced that it has signed a framework research agreement with AstraZeneca Pharmaceuticals LP to advance the latteršs efforts in the discovery and validation of novel therapeutic drug targets.Cenix will apply its ...
-
Cenix BioScience Expands Usage of Definiens Technology in High-Content Screening
(14 Feb 2008)
Definiens and Cenix BioScience GmbH announced that they have expanded their mutual licensing agreement. This strategic decision confirms the heightened commitment of Cenix to the use of the Definiens technology within its organization. Resulting ...
-
Cenix BioScience and Merck KGaA Sign Framework Agreement for RNAi-Based Drug Discovery
(05 Oct 2006)
Cenix BioScience GmbH and Merck KGaA have signed a framework research agreement securing Cenix services to enhance and accelerate Merck target discovery and validation efforts in oncology, with an option to expand in several human disease ...
-
Cenix BioScience Delivers on Target Discovery Collaboration
(11 Aug 2005)
Cenix BioScience GmbH (Dresden) announced that it has delivered a collection of potential novel therapeutic targets to one of its pharmaceutical partners, Bayer HealthCare AG (Leverkusen). The targets were identified as part of a RNAi-based ...
Additional information
Cenix BioScience GmbH
Dresden, Germany
Company
|
|
|
|
|
|
Top
